The Alpha Thalassemia Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including the rising prevalence of alpha thalassemia, advancements in treatment options, and increased awareness of genetic disorders. The market is characterized by a growing demand for...